Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy This open-label extension of the ATTRibute-CM randomized clinical trial evaluates the long-term efficacy and safety of acoramidis through month 54.

Tratamiento continuo durante 54m con acoramidis reduce la mortalidad por todas las causas y por causas CV, y la primera hospitalización por causas CV hasta los 54 m en pacientes con cardiomiopatía por amiloide transtiretina #ATTRCM #acoramidis jamanetwork.com/journals/jam...

Malattie rare, nuova terapia rimborsabile per amiloidosi cardiaca da transtiretina (Adnkronos) - Bayer annuncia che acoramidis è ora rimborsato in Italia per il trattamento dell'amiloidosi da transtiretina (Attr), sia nella forma 'wild type' sia variante, in pazienti adulti con cardiomiopatia (Attr-Cm). L'accesso all...

Malattie rare, nuova terapia rimborsabile per amiloidosi cardiaca da transtiretina ... LEGGI TUTTO #MalattieRare #Acoramidis #Amiloidosi #Cardiomiopatia #Salute

Acoramidis approved for heart condition treatment - PharmaTimes MHRA authorises drug for adults with rare heart muscle damage

#cardiology #Acoramidis #Beyonttra #Bayer #MHRA #cardiomyopathy #varianttransthyretinamyloidosis #wildtypetransthyretinamyloidosis #wildtypeATTRCM #ATTRCM #EMA #transthyretin #TTR #amyloiddeposits #Acoramidishydrochloride #TTRprotein #accesstomedicines
pharmatimes.com/news/acorami...

Poster from Jan M. Griffin, MD at #ACC.25, “The efficacy of #acoramidis compared w/ placebo was preserved, despite using more stringent thresholds for change in #NT-proBNP to indicate disease progression.” @bridgebiopharma.bsky.social #CardioSky #Cardiology #ACC25

#Acoramidis Reduces All-Cause Mortality & CV Hospitalization in Transthyretin Amyloid Cardiomyopathy #ATTR
(ATTRibute-CM)

#CardioSky #JACC
www.jacc.org/doi/10.1016/...
@jaccjournals.bsky.social @chriskramermd.bsky.social @vietheartpa.bsky.social @jgrapsa.bsky.social @psatishmd.bsky.social

Transthyretin amyloid #CMP : a paradigm for advancing precision medicine

Advances in knowledge in #transthyretin cardiac #amyloidosis and its specific Rx

#ATTR-CM #HFpEF #tafamidis #diflunisal #acoramidis #CardioEd

academic.oup.com/eurheartj/ad... @escardio.bsky.social @cardioobdoc.bsky.social

Chris De Savi: FDA Novel Drug approvals in 2024 - OncoDaily Chris De Savi: FDA Novel Drug approvals in 2024 / Acoramidis, acute leukemia, arrhythmia management, Biliary tract cancer, cancer, Cancer Cell, cell growth,

FDA Novel Drug approvals in 2024 - Chris De Savi
@fda.gov

oncodaily.com/blog/215120

#Acoramidis #AcuteLeukemia #ArrhythmiaManagement #BiliaryTractCancer #Cancer #CancerCell #CellGrowth #DrugDiscovery #FDA #GeneticDisorders #Landiolol #Medicine #OncoDaily #Oncology #Revumenib #SVTtherapies